GV and Nextech are among the participants in a series A round that is funding the launch of EQRx, which is developing cheaper copies of existing drugs.
US-based biosimilar medicine developer EQRx launched yesterday with $200m secured in a series A round featuring healthcare software provider Nextech and GV, a corporate venturing subsidiary of internet technology conglomerate Alphabet.
The corporates were joined by healthcare investment firm Casdin Capital and venture capital firms Arch Venture Partners, Andreessen Horowitz, Section 32 and Arboretum Ventures.
EQRx aims to help bring down the high cost of medicines by utilising innovative technology and science to create more affordable patent-protected versions of existing…
